论文部分内容阅读
这个试验从1979年开始,1988年结束,历时9年。试验对象为新的和复发的瘤型麻风病人358例。男280例,女78例。年龄15-60岁。病人分为二大组:组1为新病人;组2是用DDS治疗过的复发者,又各分2个小组。泰国97例病人分组I_A33例。组1_B32例,组2_A和组2_B各16例:菲律宾128例分组1_A34例,组1_c39例,组2_A27例,组2_c28例;朝鲜133例分组1_A30例,组1_D34例,组2_A40例,组2_D29例。组1_A:DDS100mg每天1次×5年,RFP1200mg开始1次;组1_B;DDS同1_A,RFP600mg每天1次D×4周;组1_c;DDS同1_A,RFP1200mg开始1次,B663 100mg1周3次×24周;组1_D:DDS同组1_A,RFP1200mg开始1次,丙硫异烟胺375mg每天1次×8周;组2_A:B663 100mg 1周3次×5年,RFP600mg每天1次×4周;组2_B:B663同组2_A,RFP600mg每天1次×2周;组2_c:B663同组2_A,RFP1200mg每4周1
The trial began in 1979 and ended in 1988, which lasted nine years. The subjects were 358 new and recurrent leprosy patients. There were 280 males and 78 females. 15-60 years old. The patients were divided into two groups: Group 1 was a new patient; Group 2 was relapsed with DDS and divided into 2 subgroups. 97 patients in Thailand group I_A33 cases. There were 16 cases in group 1_B32, group 2_A and group 2_B: 128 cases in group 1_A34 cases in Philippines, group 1_c39 cases, group 2_A27 cases and group 2_c28 cases; North Korea 133 cases group 1_A30 cases, group 1_D34 cases, group 2_A40 cases and group 2_D29 cases . Group 1_A, RFP 600 mg once daily D × 4 weeks; group 1_c; DDS same as 1_A, RFP 1200 mg once, B663 100 mg weekly for 1 week 3 × 24 weeks; Group 1_D: DDS same group 1_A, RFP 1200 mg once, prothiostan 375 mg daily x 8 weeks; Group 2_A: B663 100 mg three times a week x 5 years, RFP 600 mg daily x 4 weeks; Group 2_B: B663 same group 2_A, RFP600mg once daily x 2 weeks; group 2_c: B663 same group 2_A, RFP 1200 mg every 4 weeks 1